Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012-2016
Standard
Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012-2016. / Möhl, A; Gräfe, L; Helmeke, C; Ziehm, D; Monazahian, M; Irmscher, H-M; Dreesman, J.
in: EPIDEMIOL INFECT, Jahrgang 146, Nr. 1, 01.2018, S. 78-88.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Estimating vaccine effectiveness against laboratory-confirmed influenza among children and adolescents in Lower Saxony and Saxony-Anhalt, 2012-2016
AU - Möhl, A
AU - Gräfe, L
AU - Helmeke, C
AU - Ziehm, D
AU - Monazahian, M
AU - Irmscher, H-M
AU - Dreesman, J
PY - 2018/1
Y1 - 2018/1
N2 - Influenza vaccine effectiveness (VE) has to be estimated anew for every season to explore vaccines' protective effect in the population. We report VE estimates against laboratory-confirmed influenza A(H1N1)pdm09, A(H3N2) and influenza B among children aged 2-17 years, using test-negative design. Pooled data from two German federal states' surveillance systems for acute respiratory illness from week 40/2012 to 20/2016 was used, yielding a total of 10 627 specimens. Odds ratios and 95% confidence intervals (95% CIs) for the association between laboratory-confirmed influenza and vaccination status were calculated by multivariate logistic regression adjusting for age, sex, illness onset and federal state. VE was estimated as 1-Odds Ratio. Overall adjusted VE was 33% (95% CI: 24·3-40·7). A strong variation of VE between the seasons and subtypes was observed: highest season- and subtype-specific VE of 86·2% (95% CI: 41·3-96·7) was found against A(H1N1)pdm09 in 7-17-year-olds in 2015/16. Low estimates of VE were observed against A(H3N2) in any season, e.g. 1·5% (95% CI: -39·3-30·3) in 2014/15. Estimates showed a tendency to higher VE among 7-17-year-old children, but differences were not statistically significant. Although our findings are common in studies estimating influenza VE, we discussed several explanations for observed low VE.
AB - Influenza vaccine effectiveness (VE) has to be estimated anew for every season to explore vaccines' protective effect in the population. We report VE estimates against laboratory-confirmed influenza A(H1N1)pdm09, A(H3N2) and influenza B among children aged 2-17 years, using test-negative design. Pooled data from two German federal states' surveillance systems for acute respiratory illness from week 40/2012 to 20/2016 was used, yielding a total of 10 627 specimens. Odds ratios and 95% confidence intervals (95% CIs) for the association between laboratory-confirmed influenza and vaccination status were calculated by multivariate logistic regression adjusting for age, sex, illness onset and federal state. VE was estimated as 1-Odds Ratio. Overall adjusted VE was 33% (95% CI: 24·3-40·7). A strong variation of VE between the seasons and subtypes was observed: highest season- and subtype-specific VE of 86·2% (95% CI: 41·3-96·7) was found against A(H1N1)pdm09 in 7-17-year-olds in 2015/16. Low estimates of VE were observed against A(H3N2) in any season, e.g. 1·5% (95% CI: -39·3-30·3) in 2014/15. Estimates showed a tendency to higher VE among 7-17-year-old children, but differences were not statistically significant. Although our findings are common in studies estimating influenza VE, we discussed several explanations for observed low VE.
KW - Adolescent
KW - Child
KW - Child, Preschool
KW - Female
KW - Germany
KW - Humans
KW - Infant
KW - Influenza A Virus, H1N1 Subtype
KW - Influenza A Virus, H3N2 Subtype
KW - Influenza B virus
KW - Influenza Vaccines
KW - Influenza, Human
KW - Logistic Models
KW - Male
KW - Seasons
KW - Sentinel Surveillance
KW - Journal Article
U2 - 10.1017/S0950268817002709
DO - 10.1017/S0950268817002709
M3 - SCORING: Journal article
C2 - 29208075
VL - 146
SP - 78
EP - 88
JO - EPIDEMIOL INFECT
JF - EPIDEMIOL INFECT
SN - 0950-2688
IS - 1
ER -